Monday, October 6
8:30 am – 9:15 am
(9301-S) Emily Cooley Memorial Award and Lectureship: Lessons Learned From Pediatric Clinical Trials... and a Little Child Shall Lead Them
Director/Moderator: John W. Semple, PhD
Award Recipient: Ronald G. Strauss, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors, CEOs/CFOs, Perfusionists
Objectives:
· Analyze key clinical trials performed with infants and children as study subjects to address controversial transfusion practice issues including fresh versus stored RBC units, RBC transfusions given per liberal versus conservative pre-transfusion blood hematocrit values, and platelet transfusions given per liberal versus conservative pre-transfusion blood platelet counts.
· Hear lessons learned from these pediatric clinical trials that might be applied to transfusion practices, in general.
Event Description:
This award began as a lectureship in 1963 and was designated as a Memorial Award in 1983. The person who receives this award shall have demonstrated teaching ability and have made a major contribution to the field of immunohematology and transfusion medicine or cellular therapies.
Event Level: Intermediate
8:30 am – 10:00 am
(9303-S-CT) Novel Disease Transmission Risks of Prospective Cell-Based Transplantation Therapy
Director/Moderator: A. Bradley Eisenbrey, MD, PhD
Faculty: Kenneth McMilin, MD, PhD; Betsy Hirsch
Intended Audience: Physicians, Scientists, Technologists, Nurses
Objectives:
- Discuss the novel known and theoretical risks of stem and pluripotent cell transplantation.
Event Description: Stem and progenitor cell transplants may transmit or cause novel diseases that are not usually considered in transfusion medicine. The speakers will present their unique perspectives on the types and risks of novel diseases that may be transmitted by transplantation.
Event Level: Intermediate to Advanced
(9304-QE) Applying Risk Assessment Tools
Director/Moderator: Marge Pierce, MT(ASCP)SBB
Faculty: Lisa Walters, PhD, MBA, MT(ASCP)SBB, QSA(A2LA); Marge Pierce, MT(ASCP)SBB; Lisa Kustka, MT(ASCP)BB; Laurie Sieg, MT(ASCP)SBB
Intended Audience: Technologists, Managers/Supervisors, CEOs/CFOs
Objectives:
- Refresh knowledge and understanding of risk assessment tools.
- Understand the application of risk assessment tools to a single facility project.
- Understand the application of risk assessment tools to a multi-state multi-facility project.
Event Description: Back by popular demand, this follow up to last year's Risk Assessment session will take attendees to the next level by providing examples of how risk assessment tools have been applied to real life projects. The session will open with a brief refresher on the risk assessment tools presented last year.
Event Level: Intermediate
(9305-QE) Value Added Competency
Director/Moderator: Trish Grace, RN
Faculty: Donna Wright, RN,BSN, MS
Intended Audience: Technologists, Nurses, Managers/Supervisors
Objectives:
- Define accountabilities for employees and managers in a competency assessment program.
- Discuss a variety of methods to verify competency.
- Develop competencies that reflect organizational needs.
Event Description: Blood centers and transfusion services must perform competency assessment as required by regulatory and accreditation organizations. This workshop will offer an efficient, effective and meaningful approach to competency assessment. Participants will discover a new way of thinking about competency assessment — a way that is outcome-focused and accountability based.
Event Level: Intermediate
(9306-QE-CT) Devices for Manufacturing Cellular Therapy Products
Director/Moderator: Ellen Areman, MS, SBB(ASCP)
Faculty: Safa Karandish, MT(ASCP); Ellen Areman, MS, SBB(ASCP); Deborah Lavoie, JD, RAC
Intended Audience: Scientists, Technologists
Objectives:
- Identify risks and benefits when using medical devices for processing cellular products.
- Describe the types of safety and performance testing performed by cell therapy device manufacturers.
- Describe the regulatory processes for devices used in the manufacture and/or administration of cell therapy products.
Event Description: Today's rapidly expanding cell therapy field provides unique challenges and opportunities for development and optimization of production methods. Devices facilitating rapid and reproducible aseptic processing techniques are needed to move the industry forward. The speakers in this session will address challenges and opportunities for device manufacturers and cell therapy developers. There also will be a discussion of key regulatory issues related to the use of devices in the production and administration of cell therapy products.
Event Level: Intermediate to Advanced
(9307-RC) Global Perspectives – ADRP/AABB Joint Program
Director/Moderator: Rolf Kovenetsky
Faculty: Paul Hayes, BSc
Intended Audience: Managers/Supervisors
Objectives:
- List the challenges facing recruitment of donors in countries outside the United States.
- Understand the tactics and strategies used to ensure adequate donor recruitment occurring outside the United States.
- Learn statistical information on recruitment of donors outside the United States.
Event Description: International speakers will provide information on the status of donor recruitment efforts outside the United States. Issues affecting the donor recruitment effort will be presented along with tactics and strategies used to meet patient blood donor needs.
Event Level: Intermediate
8:30 am – Noon
(9308-LMT) Armed Services Blood Program
Director: Michael Libby, MS, MT(ASCP)SBB
Faculty: CDR, Roland, Fahie, MT(ASCP)SBB; CDR Aaron Harding, MT(ASCP)SBB; Victor MacDonald, PhD; Maj Barbara Bachman, MT(ASCP)SBB
Moderator: David Lincoln, MS, MT(ASCP)SBB, CLS(NCA)
Intended Audience: Scientists, Technologists, Managers/Supervisors
Objectives:
- Describe operations in support of the global war on terrorism.
- Update current research and development projects.
- Identify military supported humanitarian relief operations.
Event Description: This workshop will provide participants a synopsis of blood banking activities in the U.S. military. Focus will be on support to humanitarian releif operations, combat support operations and specific research and development projects sponsored by the Armed Services Blood Program.
Event Level: Intermediate
9:15 am – 10:00 am
(9302-S) Tibor Greenwalt Memorial Award and Lectureship: Conditions For Storing Platelets: History, Current Issues and Future Directions
Director/Moderator: John W. Semple, PhD
Award Recipient: Gary Moroff, PhD
Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors, CEOs/CFOs, Perfusionists
Objectives:
· Discuss the history of storing platelets for transfusion at 20 – 24°C with agitation.
· Describe the influence of interrupting continuous agitation, as occurs when platelets are shipped.
· Identify current issues relating to maintaining the quality of stored platelet components.
· Discuss the ability to store platelets with synthetic solutions and the potential for alternative platelet products.
Event Description:
This award honors Tibor Greenwalt, MD, who was the first registrant at the first AABB Annual Meeting and founding editor of TRANSFUSION. The award recognizes an individual who made major scientific or clinical contributions to hematology and transfusion medicine and succinctly communicated these advances. Acceptance of this award requires attendance at the AABB Annual Meeting and the presentation of a lecture on a current topic of interest to the transfusion medicine community.
This presentation will address an array of issues relating to the maintenance of the quality of platelets prepared for transfusion during storage. Beginning with the seminal report by Murphy and Gardner in 1969, topics to be addressed will include: the history of platelet storage, the extent of change during storage in key in vivo and in vitro platelet parameters with current and experimental procedures for the preparation/storage of platelets, and changes from interrupting agitation as occurs during shipment. In addition, future directions for new/modified ways for storing platelets, including the use of additive solutions, will also be discussed.
Event Level: Intermediate
Sponsored by Hoxworth Blood Center
10:30 am – Noon
(9309-S) New Frontiers: Platelet Bioscience
Director/Moderator: Dana Devine, PhD
Faculty: Jose Lopez, MD; Andrew Weyrich, PhD; Paul Kubes, PhD
Intended Audience: Physicians, Scientists
Objectives:
- Review the current understanding of platelet surface interactions with endothelial matrix proteins and their impact on platelet function.
- Review the role of de novo protein synthesis in platelets.
- Share recent findings of the role of the platelet as an immune effector cell.
Event Description: In this series of three scientific presentations, new areas of platelet research will be explored. The current understanding of the interaction of the platelet with the vessel wall and matrix proteins will be discussed. The role of platelets in immune function, and their ability to engage in protein synthesis suggest novel functions for this cellular component.
Event Level: Advanced
(9310-S) TTD III: Diminishing Risks from Bacterial Contamination
Director: Richard Benjamin, MD PhD
Moderator: Peter Tomasulo, MD
Faculty: Larry J. Dumont, MBA, PhD; Richard Benjamin, MD PhD; Anne Eder, MD, PhD
Intended Audience: Physicians, Scientists, Technologists, Managers/Supervisors
Objectives:
- Outline the experience of a large multi center blood program in managing and counseling donors of contaminated products.
- Describe the safety and efficacy of extended storage platelets.
- Review the state of knowledge on risk reduction through efforts to limit and reduce bacterial contamination.
Event Description: Culture systems have substantially diminished the incidence of septic reactions following platelet transfusion. Bacterial contamination of platelet products however, remains a risk to patients despite the implementation of multiple overlapping interventions to reduce and detect component adulteration during manufacture and storage. The implications for the recipients of extended storage platelets have been investigated in the PASSPORT study, a multi center protocol that extended storage to seven days. The long-term implications for the health of donors of contaminated products and the safety of future donations are not known. Presentations in this session will review the current state of knowledge with regard to the impact of platelet bacterial contamination on patient and donor safety.
Event Level: Intermediate to Advanced
(9311-S) Update on Red Blood Cell Storage
Director/Modertor: David F. Stroncek, MD
Faculty: Alan Schechter, MD; Timothy McMahon, MD, PhD; David Stroncek, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses
Objectives:
- Understand the effects of nitric oxide on blood vessels and blood flow.
- Review the biochemical interactions of nitric oxide and hemoglobin.
- Discuss the effects of red blood cell component blood storage on the levels of nitric oxide and its metabolites as well as clinical implications.
Event Description: This session will offer an overview of recent finding on the effects of storage on the levels of nitric oxide and nitric oxide metabolites. The biochemical interactions of nitric oxide with hemoglobin and their effects on vascular endothelium will be reviewed. In addition, the role of nitric oxide in the clinical complications of hemolytic anemia and a potential role in red cell transfusions will be discussed.
Event Level: Intermediate to Advanced
(9312-TC) Value of DNA Testing for Blood Groups in Patients and Donors
Director: Marion Reid, PhD, FIBMS
Moderator: Helene DePalma, MT(ASCP)SBB, CQA(ASQ)
Faculty: Connie Westhoff, PhD, MT(ASCP)SBB; Joann Moulds, PhD, MT(ASCP)SBB; Maryse St-Louis, PhD; Christine Lomas-Francis, MSc, FIBMS
Intended Audience: Physicians, Scientists, Technologists, Managers/Supervisors
Objectives:
- Describe the significance and impact of using DNA-based assays for blood group prediction on blood donors, as illustrated in the Shreveport and Hema-Quebec experiences.
- Understand the value of DNA-based testing as an adjunct to hemagglutination.
- Describe approaches to resolve discrepancies through the use of DNA analyses in conjunction with hemagglutination.
Event Description: Speakers in this program will describe the experience and impact of screening for antigen-negative in a donor center in the southern U.S. and one in eastern Canada. They also will describe how to resolve discrepancies that may arise from the prediction of blood group antigen types by DNA-based assays.
Event Level: Intermediate to Advanced
(9313-TC) New Coagulation Technologies: Will the Patient Bleed or Clot?
Director/Moderator: Mark A. Popovsky, MD
Faculty: Mark A. Popovsky, MD; Joseph Sweeney, MD; Roslyn Cohen, BFA; Alfred Stammers, MSA, CCP, PBMT
Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors, Perfusionists
Objectives:
- Identify the principles of point-of-care hemostasis assays including thromboelastography, platelet mapping and PFA 100.
- Compare the strengths and weaknesses of these assays and their value relative to older hemostasis tests.
- Identify the role of thromboelastography in the operating room in predicting the need for allogeneic transfusions.
Event Description: New point-of-care and laboratory-based hemostasis assays have been introduced over the last several years for the operating room, the intensive care unit and broader medical populations. These assays include thromboelastography (TEG), platelet function assays, and PFA-100. This program will explore the principles of these assays and the basis for the ranges that are used to interpret the tests. Experience with their efficacy in predicting the need for allogeneic transfusion or surgical intervention, particularly in cardiac surgery, will be reviewed. The relative merits of each of the newer tests compared with older, "mainstream" tests will be discussed as well.
Event Level: Intermediate to Advanced
(9314-TC) Wacky and Weird RBC Serology
Director/Moderator: Teresa Harris, MT(ASCP)SBB, CQA, CQIA(ASQ)
Faculty: Susan Johnson, MSTM, MT(ASCP)SBB; Karen Rodberg, MBA, MT(ASCP)SBB; Brooke Stuber, MT, ASCP
Intended Audience: Physicians, Technologists, Managers/Supervisors
Objectives:
- Describe how passively acquired and reagent-dependent antibodies may mimic other specificities.
- Discuss why alloantibodies and autoantibodies may not always be easy to distinguish.
- Describe reasons that antigen typing may not always be clear-cut.
Event Description: Serologic reactions in the blood bank are not always clear-cut and sometimes results are not what they originally seem. There are situations where the serologist needs to use all the available clues, including the clinical history to be able to interpret these serologic puzzles correctly. Even experienced problem-solvers expect to see specific clues to guide them to a particular resolution, but the results may lead them down the wrong path. This workshop will address three major areas where the answers are not always easily gained: 1) alloantibodies that charade as autoantibodies & autoantibodies that mimic alloantibodies 2) antibodies that are unexpected 3) antigen typings that are not clear cut or are misleading. Case studies will be presented that show what may happen to lead one down the wrong path and how enlightenment occurred.
Event Level: Intermediate to Advanced
(9315-TC) Transfusion Services in Remote and Battlefield Locations: Lessons from Iraq
Director/Moderator: J. Peter R. Pelletier, MD, MT(ASCP)
Faculty: David Kuch, MS(MCB), MT(ASCP), NCA(CLS); Kathryn Shaw, MT(ASCP)SBB
Intended Audience: Physicians, Technologists, Nurses
Objectives:
- Identify special requirements for blood products in a military operational environment.
- Describe how TEG analyzer aids in blood product utilization.
- Explain indications for fresh whole blood collections in a theater environment.
- Identify special issues with blood collections in austere environments.
Event Description: This session will address transfusion medicine in austere environments and better understanding of inventory issues secondary to long-distance supply chain and environment stressors.
Event Level: Intermediate
(9316-TC) Pediatric Transfusion: The TRIPICU Study and Beyond
Director/Moderator: Heather Hume, MD, FRCPC
Faculty: Nancy Heddle, MSc, FCSMLS(D; Jacques Lacroix, MD; Marisa Tucci, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses, Perfusionists
Objectives:
- Explain the characteristics of randomized controlled clinical trials designed to test a non-inferiority hypothesis and the correct utilization of subgroup analyses.
- Discuss the design and results of the study Transfusion Requirements in Pediatric ICUs (TRIPICU) and its applicability in clinical practice.
- Discuss what we have (and have not) learned from the TRIPICU study with respect to post-operative RBC transfusion support of pediatric cardiac surgery patients and the effect of the storage period of RBC units for transfusion of critically ill children.
Event Description: In the Transfusion Requirements in Pediatric ICUs (TRIPICU), a noninferiority trial, patients were randomly assigned to a restrictive-strategy (Hb threshold of 7 g/dL) or a liberal-strategy (Hb threshold of 9.5 g/dL) group for red-cell transfusion. The results showed that children in the restrictive strategy group received significantly fewer red-cell transfusions without increasing adverse outcomes. In this workshop, an expert in the design of clinical trials will critically evaluate the methodology used in this trial. The principal investigator of the study will explain the study details and outcome, and discuss generalibility of this study. Finally, one of the study co-investigators will discuss secondary findings that are hypothesis-generating for future studies in this important group of pediatric transfusion recipients.
Event Level: Intermediate to Advanced
(9317-TC-CT) Bench to Bedside: Translation of Cellular Therapies Products into Clinic
Director/Moderator: David H. McKenna, MD
Faculty: Diane Kadidlo, MT(ASCP)SBB; Darin Weber, PhD; Adrian P. Gee, PhD, MIBiol; Michelle Williams, PhD
Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors
Objectives:
- Appraise approaches to cell therapy product development that integrate scientific/medical, technical, quality and regulatory considerations.
- Understand the common obstacles encountered in translation of research activities to clinical production.
- Acquire skills to deal with the complexities of adopting cell therapies in the clinic.
Event Description: This session will focus on development of cell therapy products for clinical application. It will include discussion of specific examples starting at the research lab and spanning to clinical-scale production and also considerations for technical, scientific/medical, and quality/regulatory issues and approaches.
Event Level: Intermediate to Advanced
(9318-QE) Change Control Meets Validation
Director/Moderator: Jacolyn D. Leibold, MBA, MT(ASCP)SBB
Faculty: Michael Charapata, BS, MT(ASCP); Colleen Lammers, BS, BB(ASCP)
Intended Audience: Physicians, Technologists, Managers/Supervisors, CEOs/CFOs
Objectives:
- Apply effective and efficient methods for controlling change across an organization.
- Identify how validation supports change control.
- Determine what types of validation are required and define specific validation requirements through process mapping and FMEA.
- Create and review validation protocols and test plans, with or without help.
Event Description: Change is a constant in blood banks and transfusion services. Controlling change means having strong quality systems and clear validation processes. The faculty will demonstrate tools and techniques that can be used to control changes effectively within an organization. Discussion will include process mapping and hazard (or risk) analysis, both of which can be used to identify required procedural revisions, validation needs and training needs. A tool to aid in assessing validation needs also will be presented. Finally, a simplified, but effective approach toward creating and reviewing validation protocols and test plans will be discussed from the perspectives of both blood centers and transfusion services. Examples will be used to illustrate how change control and validation work together to effect change.
Event Level: Intermediate to Advanced
(9319-QE) Management of Hospital Tissue Transplant Service by the Blood Bank
Director/Moderator: A. Bradley Eisenbrey, MD, PhD
Faculty: Wendy Frizzo, MT(ASCP); Lisa Merkley, BA , MLT, CTBS
Intended Audience: Physicians, Technologists, Managers/Supervisors, CEOs/CFOs
Objectives:
- Describe differences in donor tissues available and management of tissues in Canadian and U.S. hospital tissue services.
Event Description: This session will feature a presentation on the Canadian experience with managing hospital-based tissue services and also one on a large US hospital service experience in meeting physician and patient needs for specialized tissue services.
Event Level: Intermediate
(9320-QE-CT) Overcoming Quality Challenges in Cell Processing"
Director: Thomas Lane, MD
Faculty: Raymundo Rendo III; Sufira Kiran; Fran Rabe, BA, CQM; Jose Mario Alonso, MT(ASCP); Thomas Lane, MD
Intended Audience: Technologist, Managers/Supervisors
Objectives:
· Discuss the challenges in receiving multiple types of cell therapy products from different manufacturers and collection centers.
· Describe the challenges for quality assurance in cell therapy laboratories which includes different processing techniques and the associated regulatory and accreditation requirements.
· Discuss the challenges with validations in a cellular therapy environment.
Event Description: This session will discuss topics that impact the quality processes in a cellular therapy laboratory. The topics touched upon are receipt of products, regulatory and standard requirements and validations.
Event Level: Intermediate
(9321-RC) Donor Motivation: A Research Agenda
Director: Marc Germain, MD, FRCP, PhD
Moderator: Gilles Delage, MD; George Schreiber, ScD
Faculty: Gaston Godin, PhD; Blaine Ditto, PhD; Eamonn Ferguson, PhD
Intended Audience: Physicians, Scientists, Managers/Supervisors
Objectives:
- Present and explain the recent social and behavioral research initiatives to study motivations and deterrents to blood donation.
- Compare the different theoretical frameworks used to study and modify the donation behavior.
- Discuss specific interventions that could be implemented and tested to increase the recruitment and retention of blood donors.
- Discuss on-site interventions to reduce blood donation-related symptoms.
Event Description: This session will present and discuss research initiatives in the area of donor motivation and retention, with a special focus on social and behavioral science theory around implementation intentions and altruism. The discussion will address differences between first-time and repeat donors. Experimental data based on these theories also will be presented, specifically on interventions targeted to increase the return rate among first-time donors. There also will be a discussion of on-site interventions that may reduce the chances or severity of donor reactions. The format will consist of formal lectures followed by a question period.
Event Level: Basic to Intermediate
(9322-LMT) Hemphill Jordan Leadership Award: Blood Transfusion Medicine Practices in a Developing Country
Director/Moderator: Charles Mooney
Award Recipeint: Daniel Somuah, MT
Intended Audience: Physicians, Scientists, Technologists, Nurses, Managers/Supervisors, Perfusionists
Objectives:
- Share information on decisions related to blood safety and availability in Ghana
- Describe the government’s commitment and support for a national blood policy and approaches and strategies used to ensure quality systems
- Discuss transfusion management practices
Event Description: This award honors leaders from the blood banking and transfusion medicine community, including Bernice Hemphill, W. Quinn Jordan, and Joel Solomon. The award recognizes an individual who made significant contributions in the areas of administration, quality programs, law and/or government affairs. The individual shall have demonstrated leadership qualities and a consistent willingness to lend his/her expertise to his/her peers. It may recognize one particular act or an accumulation of years of contributions.
The need for effective health care delivery is paramount in addressing the needs of all types of patient populations. This program will focus on managerial, financial and personnel issues, and what has been achieved thus far in Ghana despite numerous challenges, including recruitment of voluntary, nonremunerated blood donors, proper blood resource management and recognition, and management of transfusion reactions. Highlights of the session will include an overview of the state of the Ghana blood supply, and a look at transfusion screening and logistics, clinical status, acute donor reactions, and human resources at blood establishments. Ghana's involvement with the PEPFAR grant also will be discussed.
Event Level: Intermediate
Noon – 2:00 pm
(9324-TC-CT) Cell Therapy Sizzling Topics Discussion
Director/Moderator: Donna M. Regan, MT(ASCP)SBB
Intended Audience: Scientists, Technologists, Managers/Supervisors, CEOs/CFOs
Objectives:
- Discuss changing donor testing assays and platforms .
- Deliberate new processing techniques and emerging technologies .
- Share information about supplies and reagents specific to cellular therapy processes.
- Brainstorm practical management of cGMP and cGTP.
Event Description: This event promises an interactive session where you and your cellular therapy colleagues informally, yet candidly, discuss current topics that impact your da